arrow_back Back to App

Boosting US Drug Production, Reducing Reliance on China

This resolution suggests that government rules and taxes have made it hard for US companies to make medicines here, leading to reliance on countries like China. It calls for changes to make it easier to produce drugs in the US, aiming to improve availability and national security.
Key points
Calls for reducing taxes and rules that make it difficult to manufacture medicines in the US.
Aims to decrease reliance on foreign countries, particularly China, for essential drugs and ingredients.
Suggests promoting free market policies to strengthen US drug production and counter unfair trade practices.
Recommends improving how the government tracks where drug ingredients come from.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HRES_280
Sponsor: Rep. Jackson, Ronny [R-TX-13]
Process start date: 2021-03-26
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HRES_280.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-26.

What are the main provisions?

Key points include:

  • Calls for reducing taxes and rules that make it difficult to manufacture medicines in the US.
  • Aims to decrease reliance on foreign countries, particularly China, for essential drugs and ingredients.
  • Suggests promoting free market policies to strengthen US drug production and counter unfair trade practices.
  • Recommends improving how the government tracks where drug ingredients come from.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Jackson, Ronny [R-TX-13].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Economy Security Health